Myovant Sciences Ltd. (MYOV)
Mar 10, 2023 - MYOV was delisted (reason: acquired by Sumitovant Biopharma)
26.98
0.00 (0.00%)
Last trade price
Income Statement (Annual)
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | 230.97 | 59.32 | 0 | 0 | 0 | 0 |
| Revenue Growth (YoY) | 289.39% | - | - | - | - | - |
| Cost of Revenue | 51.55 | 1.97 | 0 | 0 | 0 | 0 |
| Gross Profit | 179.42 | 57.35 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 259.36 | 181.42 | 82.33 | 42.22 | 24.23 | 12.36 |
| Research & Development | 107.4 | 136.71 | 192.56 | 222.61 | 116.83 | 43.5 |
| Operating Expenses | 366.77 | 318.14 | 274.89 | 264.83 | 141.06 | 55.86 |
| Operating Income | -187.35 | -260.78 | -274.89 | -264.83 | -141.06 | -55.86 |
| Interest Expense / Income | 13.97 | 10.4 | 12.66 | 8.82 | 2.05 | 0 |
| Other Expense / Income | -0.38 | -16.39 | 0.68 | -0.57 | -0.07 | 27.66 |
| Pretax Income | -200.93 | -254.8 | -288.23 | -273.08 | -143.04 | -83.51 |
| Income Tax | 5.05 | 0.34 | 0.76 | 0.48 | 0.21 | -0.07 |
| Net Income | -205.98 | -255.13 | -288.99 | -273.55 | -143.26 | -83.44 |
| Shares Outstanding (Basic) | 93 | 90 | 86 | 67 | 60 | 49 |
| Shares Outstanding (Diluted) | 93 | 90 | 86 | 67 | 60 | 49 |
| Shares Change | 3.26% | 4.89% | 28.29% | 12.41% | 21.01% | - |
| EPS (Basic) | -2.22 | -2.83 | -3.37 | -4.09 | -2.41 | -1.70 |
| EPS (Diluted) | -2.22 | -2.83 | -3.37 | -4.09 | -2.41 | -1.70 |
| Free Cash Flow Per Share | -2.90 | 4.10 | -2.59 | -3.37 | -1.98 | -0.39 |
| Gross Margin | 77.68% | 96.69% | - | - | - | - |
| Operating Margin | -81.11% | -439.64% | - | - | - | - |
| Profit Margin | -89.18% | -430.12% | - | - | - | - |
| Free Cash Flow Margin | -116.70% | 621.84% | - | - | - | - |
| EBITDA | -183.89 | -241.92 | -273.8 | -263.82 | -140.75 | -83.45 |
| EBITDA Margin | -79.62% | -407.84% | - | - | - | - |
| Depreciation & Amortization | 3.07 | 2.48 | 1.77 | 0.44 | 0.24 | 0.06 |
| EBIT | -186.96 | -244.4 | -275.57 | -264.25 | -141 | -83.51 |
| EBIT Margin | -80.95% | -412.02% | - | - | - | - |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).